Martha Patricia Velandia

Dr. Martha Patricia Velandia

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Preventive Medicine
Verified
Journal Article
Open access
LBLaia Bruni
Laia Bruni
ASAnna Saura-Lázaro
Anna Saura-Lázaro
AMAlexandra Montoliu
Alexandra Montoliu
MBMaria Brotons
Maria Brotons
LALaia Alemany
Laia Alemany
PBPaul Bloem
Paul Bloem
WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.

1 June 1995 in The Lancet
Verified
Journal Article
Closed access
MVMartha Patricia Velandia
Martha Patricia Velandia
VCV. Cárdenas
V. Cárdenas
SFS.K. Fridkin
S.K. Fridkin
LBL. Bland
L. Bland
WJW. Jarvis
W. Jarvis
GRG. Ramirez
G. Ramirez

17 April 2017 in BMC Public Health
Verified
Journal Article
Open access
PDF file
AÁAlba Maria Ropero Álvarez
Alba Maria Ropero Álvarez
SPSilvia Pérez-Vilar
Silvia Pérez-Vilar
CPCarmelita Pacis-Tirso
Carmelita Pacis-Tirso
MCMarcela Contreras
Marcela Contreras
NONathalie El Omeiri
Nathalie El Omeiri
MVMartha Patricia Velandia
Martha Patricia Velandia
Over recent decades, the Region of the Americas has made significant progress towards hepatitis B elimination. We summarize the countries/territories’ efforts in introducing and implementing hepatitis B (HB) vaccination and in evaluating its impact on HB virus seroprevalence. We collected information about HB vaccination schedules, coverage estimates, and year of vaccine introduction from countries/territories reporting to the Pan American Health Organization/World Health Organization (PAHO/WHO) through the WHO/UNICEF Joint Reporting Form on Immunization. We obtained additional information regarding countries/territories vaccination recommendations and strategies through communications with Expanded Program on Immunization (EPI) managers and national immunization survey reports. We identified vaccine impact studies conducted and published in the Americas. As of October 2016, all 51 countries/territories have included infant HB vaccination in their official immunization schedule. Twenty countries, whose populations represent over 90% of the Region’s births, have included nationwide newborn HB vaccination. We estimated at 89% and 75%, the regional three-dose series and the birth dose HB vaccination coverage, respectively, for 2015. The impact evaluations of infant HB immunization programs in the Region have shown substantial reductions in HB surface antigen (HBsAg) seroprevalence. The achievements of vaccination programs in the Americas suggest that the elimination of perinatal and early childhood HB transmission could be feasible in the short-term. Moreover, the data gathered indicate that the Region may have already achieved the 2020 WHO goal for HB control.

1 March 2012 in Vaccine
Verified
Journal Article
Closed access
CCCarlos Castañeda-Orjuela
Carlos Castañeda-Orjuela
NANelson Alvis-Guzmán
Nelson Alvis-Guzmán
MVMartha Patricia Velandia
Martha Patricia Velandia
FHFernando De la Hoz-Restrepo
Fernando De la Hoz-Restrepo

30 June 2014 in BMC Public Health
Verified
Journal Article
Open access
PDF file
DLDiego Alejandro García L
Diego Alejandro García L
MVMartha Patricia Velandia
Martha Patricia Velandia
STSilas Pierson Trumbo
Silas Pierson Trumbo
MPM Cristina Pedreira
M Cristina Pedreira
PBPamela Bravo-Alcántara
Pamela Bravo-Alcántara
M. Carolina DanovaroM. Carolina Danovaro
M. Carolina Danovaro
Background: The Expanded Program on Immunization (EPI) in Colombia has made great advances since its inception in 1979; however, by 2010 vaccination coverage rates had been declining. In 2010, the EPI commissioned a nationwide study on practices on immunization, attitudes and knowledge, perceived service quality, and barriers to childhood immunization in order to tailor EPI communication strategies. Methods: Colombia’s 32 geographical departments were divided into 10 regions. Interviewers from an independent polling company administered a survey to 4802 parents and guardians of children aged <5 years in these regions. To better assess barriers to vaccination, the study was designed to have 70% of participants who had children with incomplete vaccination schedules. Explanatory factorial, principal component, and cluster analyses were performed to place participants into a group (segment) representing the primary category of reasons respondents offered for not vaccinating their children. Types of barriers were then compared to other variables, such as service quality, communication preferences, and parental attitudes on vaccination. Results: Although all respondents indicated that vaccines have health benefits, and 4738 (98.7%) possessed vaccination cards for their children, attitudes and knowledge were not always favorable to immunization. Six groups of immunization barriers were identified: 1) factors related to caregivers (24.4%), 2) vaccinators (19.7%), 3) health centers (18.0%), 4) the health system (13.4%), 5) concerns about adverse events (13.1%), and 6) cultural and religious beliefs (11.4%); groups 1, 5 and 6 together represented almost half (48.9%) of users, indicating problems related to the demand for vaccines as the primary barriers to immunization. Differences in demographics, communication preferences, and reported service quality were found among participants in the six groups and among participants in the 10 regions. Additionally, differences between how participants reported receiving information on vaccination and how they believed such information should be communicated were observed. Conclusions: Better understanding immunization barriers and the users of the EPI can help tailor communication strategies to increase demand for immunization services. Results of the study have been used by Colombia’s EPI to inform the design of new communication strategies.

12 October 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZGZacarías Garib
Zacarías Garib
AVAida Lucía Vargas
Aida Lucía Vargas
STSilas P. Trumbo
Silas P. Trumbo
KAKathleen Anthony
Kathleen Anthony
JDJose Luis Diaz-Ortega
Jose Luis Diaz-Ortega
MVMartha Patricia Velandia
Martha Patricia Velandia
Background. Despite the success of the Dominican Republic’s National Immunization Program, homogenous vaccine coverage has not been achieved. In October 2012, the country implemented a study on missed opportunities for vaccination (MOVs) in children aged <5 years.Methods. A cross-sectional study of 102 healthcare facilities was implemented in 30 high-risk municipalities. Overall, 1500 parents and guardians of children aged <5 years were interviewed. A MOV is defined as when a person who is eligible for vaccination and with no contraindications visits a health facility and does not receive a required vaccine. We evaluated the causes of MOVs and identified risk factors associated with MOVs in the Dominican Republic.Results. Of the 514 children with available and reliable vaccination histories, 293 (57.0%) were undervaccinated after contact with a health provider. Undervaccinated children had 836 opportunities to receive a needed vaccine. Of these, 358 (42.8%) qualified as MOVs, with at least one MOV observed in 225 children (43.7%). Factors associated with MOVs included urban geographic area (OR = 1.80;p=0.02), age 1–4 years (OR = 3.63;p≤0.0001), and the purpose of the health visit being a sick visit (OR = 1.65;p=0.02).Conclusions. MOVs were associated primarily with health workers failing to request and review patients’ immunization cards.